Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.
Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Cell Metab. 2020 Apr 7;31(4):679-698. doi: 10.1016/j.cmet.2020.02.014. Epub 2020 Mar 17.
25 years ago, the future of treating obesity and diabetes focused on end organs known to be involved in energy balance and glucose regulation, including the brain, muscle, adipose tissue, and pancreas. Today, the most effective therapies are focused around the gut. This includes surgical options, such as vertical sleeve gastrectomy and Roux-en-Y gastric bypass, that can produce sustained weight loss and diabetes remission but also extends to pharmacological treatments that simulate or amplify various signals that come from the gut. The purpose of this Review is to discuss the wealth of approaches currently under development that seek to further leverage the gut as a source of novel therapeutic opportunities with the hope that we can achieve the effects of surgical interventions with less invasive and more scalable solutions.
25 年前,治疗肥胖症和糖尿病的未来主要集中在已知与能量平衡和葡萄糖调节有关的终末器官上,包括大脑、肌肉、脂肪组织和胰腺。如今,最有效的治疗方法主要集中在肠道。这包括手术选择,如垂直袖状胃切除术和 Roux-en-Y 胃旁路术,它们可以产生持续的体重减轻和糖尿病缓解,但也延伸到药理学治疗,模拟或放大来自肠道的各种信号。本综述的目的是讨论目前正在开发的大量方法,这些方法试图进一步利用肠道作为新的治疗机会的来源,希望我们能够用更少的侵入性和更具可扩展性的解决方案来实现手术干预的效果。